

## SEQUENCE LISTING

<110> Biomay Produktions- und Handels-Aktiengesellschaft

<120> Process for the preparation of hypoallergenic mosaic antigens

<130> mosaic

<140>

<141>

<160> 12

<170> PatentIn Ver. 2.1

<210> 1

<211> 103

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: rearranged polypeptide sequence

<400> 1

Met Val Pro Lys Val Thr Phe Thr Val Glu Lys Gly Ser Asn Glu Lys  
1 5 10 15

His Leu Ala Val Leu Val Lys Tyr Glu Gly Asp Thr Met Ala Glu Val  
20 25 30

Glu Leu Phe Arg Phe Leu Thr Glu Lys Gly Met Lys Asn Val Phe Asp  
35 40 45

Asp Val Val Pro Glu Lys Tyr Thr Ile Gly Ala Thr Tyr Ala Pro Glu  
50 55 60

Glu Arg Glu His Gly Ser Asp Glu Trp Val Ala Met Thr Lys Gly Glu  
65 70 75 80

Gly Gly Val Trp Thr Phe Asp Ser Glu Glu Pro Leu Gln Gly Pro Phe  
85 90 95

Asn His His His His His His  
100

<210> 2  
 <211> 309  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: rearranged  
 nucleotide sequence

<400> 2  
 atgggtcccgga aggtgacggtt cacggtggag aaggggtcca acgagaagca cctggcggtg 60  
 ctggtgaagt acgaggggga caccatggcg gaggtggagc ttttcggtt cctcaccgag 120  
 aagggcatga agaacgtctt cgacgacgtc gtcccagaga agtacaccat tggggccacc 180  
 tacgcgccag aagagcggga gcacggctcc gacgagtggg tcgcatgac caagggggag 240  
 ggcggcgtgt ggacgttcga cagcgaggag ccgctccagg ggcccttcaa ccaccaccac 300  
 caccaccac 309

<210> 3  
 <211> 34  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: polypeptide

<400> 3  
 Val Pro Lys Val Thr Phe Thr Val Glu Lys Gly Ser Asn Glu Lys His  
 1 5 10 15  
 Leu Ala Val Leu Val Lys Tyr Glu Gly Asp Thr Met Ala Glu Val Glu  
 20 25 30  
 Leu Cys

<210> 4  
 <211> 33  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: polypeptide

<400> 4  
 Arg Glu His Gly Ser Asp Glu Trp Val Ala Met Thr Lys Gly Glu Gly  
 1 5 10 15

Gly Val Trp Thr Phe Asp Ser Glu Glu Pro Leu Gln Gly Pro Phe Asn  
                   20                                  25                                  30

Cys

<210> 5

<211> 32

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: polypeptide

<400> 5

Cys Phe Arg Phe Leu Thr Glu Lys Gly Met Lys Asn Val Phe Asp Asp  
   1                                  5                                  10                                  15

Val Val Pro Glu Lys Tyr Thr Ile Gly Ala Thr Tyr Ala Pro Glu Glu  
                   20                                  25                                  30

<210> 6

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 6

ggatttccat atggtcccga aggtgacgtt cacg

34

<210> 7

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 7

ggtgaggaac cggaagagct ccacctccgc catggt

36

&lt;210&gt; 8

&lt;211&gt; 36

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: primer

&lt;400&gt; 8

gcggaggtgg agctcttccg gttcctcacc gagaag

36

&lt;210&gt; 9

&lt;211&gt; 36

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: primer

&lt;400&gt; 9

ggagccgtgc tcccgtcttt ctggcgcgta ggtggc

36

&lt;210&gt; 10

&lt;211&gt; 36

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: primer

&lt;400&gt; 10

tacgcgccag aagagcggga gcacggctcc gacgag

36

&lt;210&gt; 11

&lt;211&gt; 51

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: primer

&lt;400&gt; 11

cgcgaattct cagtgggtggt ggtgggtggtg gttgaagggc ccctggagcg g 51

<210> 12

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 12

cgcgaattct cagtgggtggt ggtgggtggtg ctcttctggc gcgtaggtgg c 51